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From the carbolithiation of 6-N,N-dimethylamino fulvene (3) and 2,4[bis(N,N-dimethylamino)methyl]-N-methylpyrrolyl
lithium (2a), N-(N ,N -dimethylaminomethyl)benzimidazolyl lithium (2b)’o rp-(N,N-dimethylamino)methylphenyl lithium
(2c),thecorrespondinglithiumcyclopentadienide intermediate (4a–c)wasformed.Thesethreelithiatedintermediatesunderwent
a transmetallation reaction with TiCl4  resulting in N,N-dimethylamino-functionalised titanocenes 5a–c. When these titanocenes
were tested against a pig kidney epithelial cell line (LLC-PK), the IC50 values obtained were of 23, and 52μM for titanocenes 5a
and 5b, respectively. The most cytotoxic titanocene in this paper, 5c with an IC50 value of 13μM, was found to be approximately
two times less cytotoxic than its analogue Titanocene C (IC50 = 5.5μM) and almost four times less cytotoxic than cisplatin, which
showed an IC50 value of 3.3μM when tested on the LLC-PK cell line.
Copyright © 2008 Megan Hogan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Titanium-based reagents have signiﬁcant potential against
solid tumors. Budotitane ([cis-diethoxybis(1-phenylbutane-
1,3-dionato)titanium(IV)])lookedverypromisingduringits
preclinical evaluation, but did not go beyond Phase I clini-
cal trials, although a Cremophor EL-based formulation was
found for this rapidly hydrolysing molecule [1]. Much more
robust in this aspect of hydrolysis is titanocene dichloride
(Cp2TiCl2), which shows medium antiproliferative activity
in vitro but promising results in vivo [2, 3]. Titanocene
dichloride reached clinical trials, but the eﬃcacy of Cp2TiCl2
in Phase II clinical trials in patients with metastatic renal cell
carcinoma [4] or metastatic breast cancer [5] was too low to
be pursued.
More recently, novel methods starting from fulvenes [6–
17] and other precursors [18–20] allow direct access to
highly substituted titanocenes via reductive dimerisation,
carbolithiation, or hydridolithiation of the fulvene followed
by transmetallation in the last two cases.
TitanoceneYwasobtainedusinghydridolithiationofful-
vene,anditshowedanIC50 valueof21μM[12].Theantipro-
liferative activity of Titanocene Y h a sb e e ns t u d i e di n3 6h u -
man tumor cell lines [21] and in explanted human tumors
[22]. These in vitro and ex vivo experiments showed that
prostate, cervix, and renal cell cancers are prime targets for
these novel classes of titanocenes, whereas the IC50 values for
the breast cancer cell lines were very promising as well. These
results were underlined by ﬁrst mechanistic studies concern-
ing the eﬀect of these titanocenes on apoptosis and the apop-
totic pathway in prostate cancer cells [23]. Furthermore, ﬁrst
animal studies have been published recently, reporting the
successful treatment of xenografted Ehrlich’s ascites tumor
in mice with an ansa-titanocene [24] and xenografted Caki-
1 tumors with Titanocene Y [25], showing that the eﬀect of
Titanocene Y against xenografted Caki-1 tumors in mice was
superior to cisplatin. The structure of Titanocene Y is shown
in Figure 1.
So far, our most cytotoxic titanocene, Titanocene C (bis-
(N,N-dimethylamino-2(N-methylpyrrolyl)methylcyclo
pentadienyl) titanium (IV) dichloride, was obtained
through carbolithiation of fulvenes, which has been pub-
lished recently [26]. It has an IC50 value of 5.5μM when
tested on the LLC-PK cell line. Its structure is shown in
Figure 1. This meant signiﬁcant progress, since Cp2TiCl2
exhibits an IC50 value of only 2000μM against LLC-PK,
which explains partly the failed Phase II clinical trials against
renal cell carcinoma. The main idea behind the research
presented in this paper was to improve the cytotoxicity of
Titanocene C by adding extra dimethylamino groups using2 Metal-Based Drugs
CH3O
Ti
Cl
Cl
OCH3
Titanocene y
CH3
H3C N N
N
H H Cl
Ti
Cl
CH3
CH3
CH3
N
CH3
Titanocene C
Figure 1: Structure of Titanocenes Y and C.
the well-established Mannich reaction. Within this paper,
we present a new series of chiral titanocenes, their synthesis,
and preliminary cytotoxicity studies.
2. EXPERIMENTAL
2.1. Generalconditions
Titanium tetrachloride (1.0M solution in toluene) and butyl
lithium (2.0M solution in pentane) were obtained commer-
ciallyfromAldrichChemicalCo.(Wis,USA).THFwasdried
over Na and benzophenone, and it was freshly distilled and
collected under an atmosphere of argon prior to use. Manip-
ulations of air and moisture sensitive compounds were done
using standard Schlenk techniques under an argon atmo-
sphere. NMR spectra were measured on either a Varian 300
or a 400MHz spectrometer. Chemical shifts are reported in
ppm and are referenced to TMS. IR spectra were recorded on
a Perkin Elmer Paragon 1000 FT-IR Spectrometer employing
a KBr disk. UV/Vis spectra were recorded on a Unicam UV4
Spectrometer, while CHN analysis was done with an Exeter
Analytical CE-440 Elemental Analyser.
2.2. Synthesis
6-(N,N-dimethylamino)fulvene(3)wassynthesisedaccord-
ing to the already published procedure [27].
Synthesisofbis-(3-[2,4-di(N,N-dimethylamino)methyl]-
N-methylpyrrolyl-(N,N-dimethylamino)-methyl-
cyclopentadienyl)titanium(IV)dichloride,
{η5–C5H4–CH[N(CH3)2][C4H2(CH2–N(CH3)2)2N(CH3)]}2TiCl2
(5a)
To a Schlenk ﬂask with 2,4[bis(N,N-dimethylamino)
methyl]-N-methylpyrrole(1.61g,8.25mmol),20mlofTHF
were added until a transparent solution was formed, while
stirring at room temperature. The solution was cooled down
to −78◦C for 15minutes and 4.8mL (8.25mmol) of butyl
lithium were added. The solution was allowed to warm up to
0◦C for 20minutes, resulting in the formation of the yellow
lithium intermediate.
In a second Schlenk ﬂask, 6-(N,N-dimethylamino) ful-
vene(1.00g,8.25mmol)wasdissolvedinTHF,andtheresul-
tant orange solution was added via cannula at −78◦C to the
Schlenkﬂaskcontainingthelithiatedintermediate. Thereac-
tion mixture was then allowed to warm up to room temper-
ature and left stirring for 40minutes. Titanium tetrachloride
(4.1ml, 4.13mmol) was added afterwards in situ at room
temperature,andthemixturewasreﬂuxedfor20hours.Sub-
sequently, the solvent was removed under vacuum, resulting
in the formation of a dark brown oil that was dissolved in
dichloromethane and ﬁltered through Celite to remove the
LiCl.Theblackﬁltratewasﬁlteredadditionallytwicebygrav-
ity ﬁltration. The solvent was removed under reduced pres-
sure forming a shiny dark red solid, which was washed with
20 ml of pentaneand then dried in vacuo(1.44g, 1.93mmol,
46.8% yield).
1HN M R( δ ppm CDCl3,4 0 0 M H z ) :6 . 3 6( m ,8H ,
C5H4); 6.05 (s, 2 H, [C4H(CH2–N(CH3)2)2N(CH3)]); 3.8–
2.6 (m, 14 H, [C4H(CH2–N(CH3)2)2N(CH3)], [C4H(CH2–
N(CH3)2)2N(CH3)], [C4H(CH2–N(CH3)2)2N(CH3)]); 2.36
(s, 26 H, C4H(CH2–N(CH3)2)2N(CH3)).
13CN M R( δ ppm CDCl3, 125MHz, proton decoupled):
138, 135, 132, 126, 121, 119, 108 [C5H4 and C4H(CH2–
N(CH3)2)2N(CH3)]; 52 [C5H4–CH–(N(CH3)2)(C4H(CH2–
N(CH3)2)2N(CH3)]; 34, 32 [N(CH3)2 and C4H(CH2–
N(CH3)2)2N(CH3)].
IRabsorptions(cm−1 KBr):3414,2917,2769,1620,1466,
1382, 1018.
Anal. Calc. for C38H62N8TiCl2: C, 60.87; H, 8.35; N,
14.95; Cl, 9.46; Found: C, 59.80; H, 8.29; N, 14.18; Cl, 9.45.
UV-Vis (CH2Cl2): λ 244nm (ε 10833), λ 330nm (ε
12996), λmax 510nm (weak).
Synthesisofbis-[(N,N-dimethylaminomethyl-
2-benzimidazolyl)(N ,N dimethylamino)
methylcyclopentadienyl]titanium(IV)dichloride,
{η5–C5H4–CH[N(CH3)2][C10H12N3]}2TiCl2 (5b)
To a Schlenk ﬂask with N-(N ,N -dimethylaminomethyl)
benzimidazol (1.45g, 8.25mmol), 20ml of THF were added
until a transparent solution was formed, while stirring at
room temperature. The solution was cooled down to −78◦C
for 15minutes and 14.0ml (8.25mmol, 1.7M) of butyl
lithium were added. The solution was allowed to warm upMegan Hogan et al. 3
to 0◦C for 20minutes, resulting in the formation of the yel-
low lithium intermediate.
In a second Schlenk ﬂask, 1.00g (8.25mmol) of 6-
N,N-dimethylamino fulvene was dissolved in THF, and the
resultant red solution was added via cannula at −78◦C to the
Schlenkﬂaskcontaining thelithiatedintermediate. Thereac-
tion mixture was then allowed to warm up to room temper-
ature and left stirring for 40minutes. Titanium tetrachloride
(4.1ml, 4.13mmol) was added afterwards in situ at room
temperature and the mixture was reﬂuxed for 20h. Subse-
quently, the solvent was removed under vacuum, resulting
in the formation of a dark green oil that was dissolved in
dichloromethane and ﬁltered through Celite to remove the
LiCl.Theblackﬁltratewasﬁlteredadditionallytwicebygrav-
ity ﬁltration. The solvent was removed under reduced pres-
sure forming a shiny black solid, which was washed with
20ml of pentane and then dried in vacuo (1.97g, 2.77mmol,
67.3% yield).
1HN M R( δ ppm CDCl3, 400MHz): 7.80–7.82 [m, 4H,
C5H4 –CH[N(CH 3)2]–C–N–C–CH–CH–CH–CH–C–N
(CH2N(CH3)2)]; 7.49–7.51 [m, 4 H, C5H4–CH[N(CH3)2]–
C–N–C–CH–CH–CH–CH–C–N(CH2N(CH3)2]; 6.42–6.71
[m, 8H, C5H4–CH[N(CH3)2]–C7H4NN–CH2−N( C H 3)2];
4.85 [s, 4H, C5H4–CH[N(CH3)2]–C7H4NN–CH2−N
(CH3)2]; 4.00 [m, 2H, C5H4–CH[N(CH3)2]–C7H5N2–
CH2−N–(CH3)2]; 2.16, 2.23, 2.34 [s, 24H, C5H4–CH
[N(CH3)2]–C7H5N2–CH2−N–(CH3)2].
13CN M R( δ ppm CDCl3, 125MHz, proton decoupled):
144, 142, 136, 135, 132, 126, 123, 122, 121, 120, 119,
112[C5H4–CH[N(CH3)2]–C7H5N2–CH2−N–(CH3)2]; 69,
68,64,44,43,36,34,32,23,28,19,14,13[C5H4–CH[N(CH3)2]–
C7H5N2–CH2−N–(CH3)2].
IRabsorptions(cm−1 KBr):3429,2926,1635,1456,1270,
1039, 861, 743.
Anal. Calc. for C36H46N8TiCl2: C, 60.93; H, 6.53; N,
15.79; Cl, 9.99 Found: C, 59.99; H, 6.52; N, 15.72; Cl, 9.99.
UV-Vis (CH2Cl2): λ 230nm (ε 22770), λ 402nm (ε
2020), λ 499nm (ε 210), λmax 523nm (weak).
Bis-(N,N-dimethylamino)-p-(N,N-dimethyl-
amino)methylphenylcyclopentadienyl)
titanium(IV)dichloride,
{η5-C5H4–CH[N(CH3)2][C6H4CH2N(CH3)2]}2TiCl2 (5c)
To a Schlenk ﬂask with 0.37g (1.73mmol) p-(N,N-
dimethylamino)methylphenylbromide, 14ml of THF were
added until a transparent solution was formed, while stir-
ring at room temperature. The solution was cooled down
to −78◦C and 1.02ml (1.73mmol, 1.7M) of t-butyl lithium
were added. The solution was allowed to warm up to 0◦Cf o r
20minutes, resulting in the formation of the yellow lithium
intermediate.
In a second Schlenk ﬂask, 0.21g (1.73mmol) of 6-(N,N-
dimethylamino) fulvene was dissolved in THF, and the re-
sultant red solution was added via cannula at −78◦C to the
Schlenk ﬂask containing the lithiated intermediate. The re-
action mixture was then allowed to warm up to room tem-
perature and left stirring for 40minutes. Titanium tetrachlo-
ride (0.86ml, 0.86mmol) was added afterwards in situ at
room temperature and the mixture was reﬂuxed for 20h.
Subsequently, the solvent was removed under vacuum, re-
sulting in the formation of a dark brown oil that was dis-
solved in dichloromethane and ﬁltered through Celite to re-
move the LiCl. The black ﬁltrate was ﬁltered additionally
twice by gravity ﬁltration. The solvent was removed under
reduced pressure forming a shiny dark brown solid, which
was washed with 150ml of pentane and then dried in vacuo
(0.45g, 0.71mmol, 82.7% yield).
1HN M R( δ ppm CDCl3, 300MHz): 7.73–7.43 [m, 8H,
C6H4CH2N(CH3)2]; 6.70–6.40 [m, 8H, C5H4]; 3.14 [s, 2H,
C5H4–CH–(N(CH3)2(C6H4CH2N(CH3)2)]; 4.25–4.21 [s,
4H, C5H4–CH–(N(CH3)2(C6H4CH2N(CH3)2)]; 2.84–2.81
[s, 12H, C5H4–CH–(N(CH3)2(C6H4CH2N(CH3)2)]; 2.81–
2.77 [s, 12H, C5H4–CH–(N(CH3)2(C6H4CH2N(CH3)2)].
13CN M R( δ ppm CDCl3, 125MHz, proton decoupled):
146, 138, 136, 132, 131, 129, 127, 124, 120 [(C6H4
CH2N(CH3)2)a n d( C 5H4)]; 61 [C5H4–CH–(N(CH3)2
(C6H4CH2N(CH3)2))]; 60 [(C6H4CH2N(CH3)2)]; 42
[C5H4–CH–(N(CH3)2(C6H4CH2N(CH3)2))].
IRabsorptions(cm−1 KBr):3444,3391,2958,2670,2470,
1621, 1467, 1411, 1261, 1164, 1071, 1013, 943, 798.
Anal. Calc. forC34H46N4TiCl2: C, 64.90; H, 7.37; N, 8.91;
Cl, 11.27 Found: C, 64.88; H, 7.36; N, 8.90; Cl, 11.27.
UV-Vis (CH2Cl2): λ 263nm (ε 86000), λ 275nm (ε
94000), λ 298nm (ε 98000), λ 320nm (ε 108000), λ 340nm
(ε 72000), λ 390nm (ε 35000), λmax 455nm (weak).
3. RESULTS AND DISCUSSION
3.1. Synthesis
6-(N,N-dimethylamino)fulvene(3)wassynthesisedaccord-
ing to the already published procedure [27], and its structure
is shown in Scheme 1.
The use of aryl lithium in the synthesis of other metal-
locenes is well known [28–30], and it has recently been used
for the synthesis of chiral titanocene dichlorides [26].
Thistime,thecarbolithiationmethodledtothesynthesis
ofanewgroupoftitanocenesthatcontainstereocentres(5a–
c).
The ﬁrst step of the reaction consists of the formation
of the functionalised lithium intermediates (2a–c) by react-
ing the corresponding heterocycles (1a–c) with tert-butyl
lithium. Side reactions were avoided by cooling the reaction
down to −78◦C during the addition of tert-butyl lithium,
and subsequent warming up to 0◦C.
This step was followed by a nucleophilic addition of
the lithiated intermediate to the double bond of 6-N,N-
dimethylamino fulvene at −78◦C. Then the reaction mix-
ture was allowed to warm up to 0◦C, resulting in the for-
mation of the appropriately substituted lithium cyclopen-
tadienyl intermediates 4a–c. This reaction occurs with no
stereo-selectivity, and the intermediates 4a–c already contain
a stereogenic carbon.
After stirring the reaction mixture for 40minutes, two
molar equivalents of 4a, 4b or 4c underwent a transmetalla-
tion reaction when reacted with TiCl4 under reﬂux over 20h
in THF to give titanocenes 5a–c.4 Metal-Based Drugs
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The compounds obtained are shiny dark red solids. The
synthesis of these compounds is shown in Scheme 1.
All three titanocenes shown in this paper have diﬀerent
i s o m e r sa ss e e ni nFigure 1. As a result of this, three diﬀerent
signals should be seen for every proton and carbon in the 1H
and 13C NMR spectra. The R,R and S,S isomers are enan-
tiomers and thus give identical NMR spectra, whereas for
protons or carbons corresponding to the R,S (same as S,R)
isomer, two signals can be observed as the environment of
the two cyclopentadienyl rings is diﬀerent. A relation of 2 : 1
: 1 for S,S and R,R, and the two signals for the S,R (or R,S)
isomers can be observed in the integration pattern.
3.2. Cytotoxicitystudies
Preliminaryin vitro cell tests were performed on LLC-PK
cells in order to compare the cytotoxicity of the compounds
presented in this paper. This cell line was chosen based on
their long-lasting growth behavior, similar to the one shown
in carcinoma cells. It was obtained from the ATCC (amer-
ican tissue cell culture collection) and maintained in Dul-
becco’s modiﬁed Eagle medium containing 10% (v/v) FCS
(foetalcalfserum),1%(v/v)penicillinstreptomycin,and1%
(v/v) L-glutamine. Cells were seeded in 96-well plates con-
taining 200 μl microtiter wells at a density of 5,000-cells/200
μl of medium and were incubated at 37◦Cf o r2 4 ht oa l -
low for exponential growth. Then the compounds used for
the testing were dissolved in the minimalamount of DMSO
(dimethylsulfoxide)possibleanddilutedwithmediumtoob-
tain stock solutions of 5 × 10−4 M in concentration and less
than0.7%ofDMSO.Thecellswerethentreatedwithvarying
concentrationsofthecompoundsandincubatedfor48hours
at 37◦C. Then the solutions were removed from the wells,
the cells were washed with PBS (phosphate buﬀer solution),
and fresh medium was added to the wells. Following a re-
covery period of 24h incubation at 37◦C, individual wells
were treated with a 200μl of a solution of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in
medium.Thesolutionconsistedof30mgofMTTin30mlof
medium. The cells were incubated for 3hours at 37◦C. The
medium was then removed and the purple formazan crys-
tals were dissolved in 200μL DMSO per well. Absorbance
was then measured at 540nm by a Wallac Victor (Multilabel
HTS Counter) Plate Reader. Cell viability was expressed as a
percentage of the absorbance recorded for control wells. The
valuesusedforthedoseresponsecurvesofFigure 2represent
the values obtained from four consistent MTT-based assays
for each compound tested.
As seen in Figure 2,T i t a n o c e n e s5a–c showed an IC50
value of 23, 52, and 13μM, respectively.
When compared to unsubstituted titanocene dichloride
(IC50 value = 2000μM), titanocene 5c shows a major de-
crease in magnitude in terms of the IC50 value, and approx-
imately a fourfold increase in magnitude with respect to cis-
platin itself (IC50 value = 3.3μM). However, titanocene 5c
showsadecreaseincytotoxicitywithrespecttoTitanoceneC.
The increased polarity of the new titanocenes together withMegan Hogan et al. 5
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Figure 2: Cytotoxicity studies of Titanocenes 5a–c against LLC-PK
cells.
an increase in size might be the cause of the decrease in cyto-
toxicity shown.
3.3. StructuralDFTdiscussion
Despite our eﬀorts to crystallise these three titanocenes, no
crystal structures were obtained. This might be explained by
the existence of diﬀerent isomers in the racemic mixture. In
order to overcome this problem, density functional theory
(DFT) calculations were carried out for titanocene 5c at the
B3LYP level using the 6-31G∗∗ basis set [31], and compared
with that of Titanocene C [26].
Selected bond lengths of the optimised structure of ti-
tanocenes 5a and C are listed in Table 1 (for atom number-
ing, see Scheme 2). The calculated structure of 5c is pre-
sented in Figure 3.
The length of the bond between the metal centre and the
cyclopentadienyl carbons is slightly diﬀerent for the diﬀerent
Cp rings (251.3 and 248.5pm, resp.). The same applies for
the carbon-carbon bonds of the cyclopentadienyl rings with
bond lengths between 140.2 and 143.4pm.
The bond length between the methylic carbon centre
and the carbon centre of the Cp group is of 152.2 and
152.0pm, respectively. As well, the length of the bond be-
tween the methylic carbon and the nitrogen of the dimethy-
lamino group is almost identical in all cases, and between
152.0 and 148.2pm, respectively. The steric impediment of
the dimethylamino groups attached to the methylic carbons
causes a lengthening of the bond, in order to relieve the re-
sultant steric strain.
The Cl–Ti–Cl angle was calculated to be 95.1◦. The angle
formed between C1 and C1 , the respective methylic carbons
(C6 or C6 ), and C7 or C7 , respectively, was of 11.42◦ in both
cases, and almost identical to the one formed between each
Table 1: Selected bond lengths from the DFT-calculated structure
of 5c and DFT-calculated structure of Titanocene C.
DFT structure (5c) DFT structure Titanocene C
Bond length (pm) Bond length (pm)
Ti−C1 251.3 250.4
Ti−C2 242.9 242.8
Ti−C3 244.2 240.0
Ti−C4 240.4 237.4
Ti−C5 243.2 242.9
Ti−C1  248.5 247.8
Ti−C2  239.1 239.0
Ti−C3  234.2 233.1
Ti−C4  245.6 243.7
Ti−C5  250.2 249.3
C1−C2 143.4 143.2
C2−C3 141.6 141.5
C3−C4 141.2 141.3
C4−C5 142.3 142.3
C5−C1 141.4 141.4
C1 −C2  141.4 141.4
C2 −C3  142.2 142.4
C3 −C4  142.3 142.2
C4 −C5  140.2 140.2
C5 −C1  143.0 143.0
C1−C6 152.2 152.2
C1 −C6  152.2 152.0
C6−C6  559.5 559.5
C6−C7 151.5 152.0
C6 −C7  152.0 151.5
C6−N1 152.0 148.3
C6 −N2 149.7 148.4
Ti−Cl1 240.5 234.9
Ti−Cl2 234.1 236.1
nitrogen of the dimethylamino group, C6 or C6 ,a n dC 1 and
C1 , respectively.
The DFT calculated structure of 5a was then compared
to the calculated structure of its mono-N-methylpyrrolyl-
substitutedanalogue,TitanoceneC[26].Inthiscomplex,the
length of the bond between the titanium centre and the two
Cl atoms appeared to diﬀer in only 1pm approximately from
theonefoundfor5c,andof234.9and236.1pm,respectively.
The same applies to the bond length between the N1 or N2
and C6 or C6 , respectively, and to the length of the bond be-
tween the Cp carbon atoms and the titanium centre.
The Cl–Ti–Cl angle in Titanocene C is very similar to the
onecalculatedfor5c,andof94.9◦,andsoistheangleformed
between the titanium centre and the centre of the Cp rings
(with a diﬀerence of 0.3◦).
Selected bond lengths from the calculated DFT structure
of Titanocene C are listed in Table 1, while atom numbering
can be seen in Scheme 2.6 Metal-Based Drugs
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Figure 3: DFT calculated structure of 5c.
The cartesian coordinates for the DFT optimised struc-
ture of titanocene 5C can be observed in the supplementary
material, where the energy of optimisation is also found.
4. CONCLUSIONSAND OUTLOOK
The carbolithiation of 6-(N,N-dimethylamino) fulvene
with Mannich-functionalised lithiated species followed by
transmetallation oﬀers a general way into the synthesis
of new chiral N,N-dimethylamino-functionalised metal-
locenes. Derivative 5c exhibits an impressive cytotoxicity
with an IC50 value of 13μM against LLC-PK cells, but is
slightly less active with respect to Titanocene C that shows
the highest cytotoxicity for a published titanocene so far.
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